Stay updated on Apremilast-Dupilumab Combo in Eczema Clinical Trial
Sign up to get notified when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.

Latest updates to the Apremilast-Dupilumab Combo in Eczema Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check21 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check28 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check64 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about a study on apremilast for atopic dermatitis, while adding a new version revision and collaborators.SummaryDifference36%
Stay in the know with updates to Apremilast-Dupilumab Combo in Eczema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.